Platinum Investment Management Ltd. decreased its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 370,278 shares of the company's stock after selling 59,423 shares during the period. Platinum Investment Management Ltd. owned approximately 0.28% of Centessa Pharmaceuticals worth $6,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CNTA. Janus Henderson Group PLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at approximately $20,698,000. Franklin Resources Inc. increased its holdings in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after acquiring an additional 953,659 shares during the period. Baker BROS. Advisors LP boosted its stake in shares of Centessa Pharmaceuticals by 123.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company's stock worth $19,623,000 after acquiring an additional 677,966 shares in the last quarter. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $4,951,000. Institutional investors and hedge funds own 82.01% of the company's stock.
Centessa Pharmaceuticals Price Performance
Shares of NASDAQ:CNTA traded down $0.54 during trading on Friday, reaching $15.75. The stock had a trading volume of 1,555,582 shares, compared to its average volume of 526,428. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The stock has a market cap of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54. The business has a fifty day moving average price of $16.47 and a 200-day moving average price of $16.40.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on CNTA shares. Guggenheim reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Morgan Stanley reiterated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $26.00.
Read Our Latest Stock Report on CNTA
Insiders Place Their Bets
In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now directly owns 118,265 shares of the company's stock, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the insider now owns 183,266 shares of the company's stock, valued at $3,122,852.64. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock valued at $4,316,568 in the last 90 days. 11.59% of the stock is owned by insiders.
About Centessa Pharmaceuticals
(
Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
